rwj-67657 and Encephalitozoonosis

We recently showed that the pyridinylimidazoles SB203580 and SB202190, drugs designed to block human p38 mitogen-activated protein kinase (MAPK) activation, also inhibited replication of the medically important intracellular parasite Toxoplasma gondii in cultured human fibroblasts through a direct effect on the parasite. We now show that additional pyridinylimidazole and imidazopyrimidine p38 MAPK inhibitors inhibit intracellular T. gondii replication in vitro and protect mice against fatal T. gondii infection. Mice surviving infection following treatment with p38 MAPK inhibitors were resistant to subsequent T. gondii challenge, demonstrating induction of protective immunity. Thus, drugs originally developed to block human p38 MAPK activation are useful for treating T. gondii infection without inducing significant immunosuppression. MAPK inhibitors combined with either of the approved anti-Toxoplasma drugs sulfadiazine and pyrimethamine resulted in improved survival among mice challenged with a fatal T. gondii inoculum. A MAPK inhibitor also treated mice infected with the Microsporidium parasite Encephalitozoon cuniculi, suggesting that MAPK inhibitors represent a novel class of agents that may have a broad spectrum of antiparasitic activity. Preliminary studies implicate a T. gondii MAPK homologue as the target of drug action, suggesting possibilities for more-selective agents.

Topics: Animals; Antiprotozoal Agents; CD8 Antigens; Dose-Response Relationship, Drug; Drug Design; Drug Synergism; Drug Therapy, Combination; Encephalitozoon cuniculi; Encephalitozoonosis; Enzyme Inhibitors; Female; Humans; Imidazoles; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; p38 Mitogen-Activated Protein Kinases; Pyridines; Time Factors; Toxoplasma; Toxoplasmosis, Animal